WEBULL
WebtradeDownload

Danaher (DHR) Stock Looks Reasonable After New FDA Cleared Test News

Simply Wall St · 1d ago

Danaher has quietly stacked up a 18.1% return over the past 3 years, helped by stronger earnings expectations and fresh product news from its diagnostics arm, so the live question is whether that performance lines up with the cash the business is expected to generate. With a Discounted Cash Flow (DCF) estimate available, the stock invites a closer look at how its current price of US$230.11 relates to those underlying cash flows rather than just headline momentum.

  • Over the past 3 years the share price has gained 18.1%, which puts real weight on whether the cash flow outlook can support that kind of compounding from here.
  • Fresh products like Cepheid's newly cleared Xpert Hemorrhagic Fever Panel may support expectations for future testing volumes and, in turn, the timing and durability of Danaher's cash generation from its diagnostics platforms.
  • If you'd rather focus on earnings, this one's for you. See what Danaher's 37.7x P/E says about the price.

For investors, the debate is whether Danaher's current share price is adequately explained by the cash flows implied in its Discounted Cash Flow (DCF) intrinsic value estimate.

If you are weighing Danaher against other businesses through the same lens of cash generation, it can help to compare its setup with companies in the our screener containing 19 high quality undiscovered gems

Does Danaher Look Fairly Valued on Cash Flow?

The Discounted Cash Flow (DCF) model here focuses on the cash Danaher can return to shareholders over time. Latest twelve month free cash flow sits at about $5.6b, and the projections assume this pool of cash grows steadily into the early 2030s rather than spiking sharply in any one year.

On that set of cash flow estimates, the DCF outcome suggests an intrinsic value that is broadly in line with the current share price of $230.11. The recent FDA clearance for Cepheid's Xpert Hemorrhagic Fever Panel gives some context for those growth assumptions, because it points to additional test volumes feeding into that projected cash generation from Danaher's diagnostics platforms. Find out what Danaher could be worth using our Discounted Cash Flow (DCF) estimate.

The Danaher Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where the Danaher valuation question leaves off by spelling out which assumptions on growth, margins and earnings would need to hold for the stock to look meaningfully mispriced relative to today's cash flow view. Each narrative links Danaher's potential catalysts and key risks to a single fair value estimate so you can track over time which version of the story appears to be gaining traction on the Community page.

One of the top community narratives on Danaher: 11% undervalued

"Analysts expect Danaher to continue compounding its mix of recurring consumables and diagnostics revenue, while converting earnings into strong free cash flow..."

Discover why this Narrative puts Danaher at 11% undervalued.

For Danaher, the next question is who is steering the ship

Valuation only tells part of the story for Danaher, because the track record, decisions and pay structure of the leadership team can heavily influence how those cash flows are pursued and prioritized. See who runs Danaher and how they are paid.